Tofacitinib-d 3 citrate

Overview

Tofacitinib-d 3 (citrate) is deuterium labeled Tofacitinib (citrate). Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial , antifungal and antiviral activities.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Others | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > JAK | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Bacterial | Products > Signaling Pathways > Fungal | Products > Signaling Pathways > Influenza Virus | Products > Signaling Pathways > Isotope-Labeled Compounds

Product Information

• Catalog No.: HY-40354AS
• CAS No.: 2701680-77-3
• Molecular Formula: C22H25D3N6O8
• Molecular Weight: 507.51
• Purity: 99.53%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Availability: In-stock

Source

Original product source